GlassScriptPhysician profile
David Aaron Guerra
NPI 1255986204
$2,227.18
in general payments reported to CMS, 2019-2025
30 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $67.23 · 2023: $28.56 · 2024: $345 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $332.74 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $310.55 | 2024-2025 | Korlym |
| Lilly USA, LLC | $262.74 | 2022-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $146.19 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.23 | 2024-2025 | |
| Amgen INC. | $124.23 | 2021-2025 | Tepezza, Repatha |
| Neurocrine Biosciences, INC. | $85.96 | 2024-2025 | |
| Madrigal Pharmaceuticals | $79.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $74.96 | 2021-2025 | |
| Ascendis Pharma Endocrinology INC | $73.97 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $71.38 | 2025 | Unithroid |
| Mannkind Corporation | $63.73 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.52 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $40.19 | 2025 | Recorlev, Gvoke Hypopen |
| Abbott Laboratories | $39.13 | 2025 | Freestyle Libre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $38.69 | 2025 | Isturisa |
| Amarin Pharma, INC. | $37.00 | 2021 | |
| Esperion Therapeutics, INC. | $30.18 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $29.04 | 2021 | |
| Tandem Diabetes Care, INC. | $27.35 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Gilead Sciences, INC. | $23.08 | 2024 | Biktarvy |
| Sanofi-Aventis U.S. LLC | $22.95 | 2021 | |
| Hologic Sales and Service, LLC | $22.08 | 2021 | |
| Ibsa Pharma INC. | $20.74 | 2025 | Licart, Flector, Tirosint |
| Insulet Corporation | $18.19 | 2025 | Omnipod |
| Dexcom, INC. | $16.92 | 2024 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $16.88 | 2024 | Cabenuva |
| Sequel Med Tech, LLC | $14.11 | 2025 | Twiist |
| Bioventus LLC | $12.83 | 2022 | |
| Merck Sharp & Dohme LLC | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Guerra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.